Our products
26 October 2022
5 September 2022
Polpharma’s strategic investment in HPAPI facility, the first of this kind in Poland
5 September 2022
Safe approach in delivering nitrosamine-free API products
3 August 2022
Zoledronic acid
21 July 2022
Polpharma partners with Pikralida biopharmaceutical start-up
13 July 2022
Xylometazoline hydrochloride
13 July 2022
Vardenafil hydrochloride
13 July 2022
13 July 2022
Tolterodine tartrate
13 July 2022
Polpharma’s strategic investment in HPAPI facility
We have launched an investment in a specialized facility
for the R&D and Production of highly active substances
with an OEL value of 10 ng/m3 (OEB 6).

The HP API investment includes separate process
laboratories (PDL), analytical laboratories (ADL)
with the possibility of performing Quality Control
analyses, and a GMP kilo-lab production line with
volume up to 1.5 kg with potential volume increase.